COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS ALENDRONATE FOR POSTMENOPAUSAL OSTEOPOROSIS IN SOUTH KOREA

被引：2
|
作者：
Bae, G. [1 ]
Kwon, H. [2 ]
An, J. [3 ]
Park, J. [3 ]
机构：
[1] Ewha Womans Univ, Seoul, South Korea
[2] Mokwon Univ, Daejeon, South Korea
[3] Amgen Korea, Seoul, South Korea
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.613
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS20
引用
收藏
页码：S82 / S82
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY OF DENOSUMAB FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN COLOMBIA
    Perlaza, Garcia J.
    Arocho, R.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A541 - A541
  • [2] COST-UTILITY OF DENOSUMAB FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SPAIN
    Darba, J.
    Kaskens, L.
    Sorio, F.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A311 - A311
  • [3] Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
    Darba, Josep
    Kaskens, Lisette
    Vilela, Francesc Sorio
    Lothgren, Mickael
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 105 - 117
  • [4] COST-UTILITY OF DENOSUMAB FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
    Hiligsmann, M.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 16 - 16
  • [5] Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis
    Taheri, Saeed
    Fashami, Fatemeh Mirzayeh
    Peiravian, Farzad
    Yousefi, Nazila
    [J]. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (02): : 1073 - 1085
  • [6] COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS STANDARD CARE IN THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN PORTUGAL
    Cristino, J.
    Canhao, H.
    Perelman, J.
    Santos, C.
    Pereira, J.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A128 - A128
  • [7] COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS RALOXIFENE FOR TREATING OSTEOPOROSIS IN POST-MENOPAUSAL WOMEN IN THE UNITED STATES
    Beaubrun, A. C.
    Daugherty, J. B.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A129 - A129
  • [8] Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
    Cha, Seungju
    Sohn, Minjeong
    Yang, Hyowon
    Yeh, Eric J.
    Baek, Ki-Hyun
    Ha, Jeonghoon
    Ku, Hyemin
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2024, 25 (01)
  • [9] Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
    Seungju Cha
    Minjeong Sohn
    Hyowon Yang
    Eric J. Yeh
    Ki-Hyun Baek
    Jeonghoon Ha
    Hyemin Ku
    [J]. BMC Musculoskeletal Disorders, 25
  • [10] Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US
    Parthan A.
    Kruse M.
    Yurgin N.
    Huang J.
    Viswanathan H.N.
    Taylor D.
    [J]. Applied Health Economics and Health Policy, 2013, 11 (5) : 485 - 497
12345